Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GMAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Genmab files annual reports on Form 20‑F and furnishes current reports on Form 6‑K under the Securities Exchange Act of 1934. These filings cover a wide range of topics, from interim financial results and capital increases to equity awards, articles of association and material company announcements.
Recent Forms 6‑K referenced in the available data include interim reports, company announcements about net sales of partnered products such as DARZALEX, capital increases resulting from employee warrant exercises, grants of restricted stock units and warrants, and disclosures related to the proposed acquisition of Merus N.V. and associated financing. Other 6‑K filings incorporate company announcements on regulatory milestones for EPKINLY (epcoritamab‑bysp), portfolio prioritization decisions and updates on late‑stage clinical programs.
Because Genmab uses its 6‑K reports to furnish key announcements to U.S. investors, these filings can be a primary source for understanding changes in its capital structure, details of tender offers and acquisitions, and the status of important clinical and commercial programs. On Stock Titan, users can review these documents alongside AI‑powered summaries that explain the context and main points of each filing, helping to interpret technical content in forms such as 6‑K and 20‑F.
Investors researching GMAB can use this page to follow how Genmab reports on its antibody platforms, collaborations, late‑stage pipeline, financing arrangements and governance documents over time. The combination of real‑time EDGAR updates and AI‑generated insights is intended to make it easier to navigate lengthy filings and identify information relevant to Genmab’s business and capital markets activity.
Genmab A/S has filed a Form 6-K reporting transactions related to its ongoing share buy-back program for the period of June 16-20, 2025. The filing includes two key exhibits:
- A company announcement dated June 23, 2025, detailing transactions connected to the share buy-back program
- An appendix providing specific details of the share buyback program's execution for the week of June 16-20, 2025
The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer. This Form 6-K will be incorporated by reference into Genmab's multiple S-8 registration statements (File Numbers: 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876). The company continues to file annual reports under Form 20-F as a foreign private issuer.